ABT-089
DrugSubjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
NCT Number: NCT00528697
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention-Deficit/Hyperactivity Disorder or ADHD.
Looking for future studies?
Notify Me6 year–12 year
All sexes
Interventional
Phase 2
Site Reference ID/Investigator# 5999, Little Rock, Arkansas, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
Subject will take a tablet once daily for 8 weeks
Time frame: Screening, Day -1, Day 7, Day 14, Day 28, Day 42, Day 56
Time frame: Baseline to Final Evaluation of 8-week treatment period
Time frame: Baseline to Final Evaluation of 8-week treatment period
Time frame: Baseline to Final Evaluation of 8-week treatment period
Time frame: Baseline to Final Evaluation of 8-week treatment period
AbbVie (prior sponsor, Abbott)
Industry
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07633275
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Changsha, Hunan, China
View Trial DetailsNCT06185985
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
New York, United States
View Trial DetailsNCT01342445
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Bethlehem, Pennsylvania, United States
View Trial DetailsNCT05778526
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Hong Kong
View Trial Details